| Name | Title | Contact Details |
|---|
MC-21 is a Caguas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ayurvedic Center Inc is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Frantz Medical Group is a Mentor, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fresno Surgical Hospital (FSH) is a fully-licensed, Joint Commission-accredited hospital that delivers award-winning surgical care and patient satisfaction. We are a physician-owned hospital that focuses solely on providing advanced, affordable surgical care. Each year, FSH serves approximately 12,000 patients in our Central California service area including: Fresno, Madera, Merced, Kings and Tulare Counties. Our patients enjoy a non-traditional, hotel-like setting and a commitment to quality care and patient satisfaction. Twenty-seven private inpatient suites give patients and their families an environment that promotes relaxation, comfort and healing. FSH was founded by two orthopedic surgeons, Alan H. Pierrot, MD and Thomas Thaxter, MD, who had a vision of improving healthcare. Originally named Fresno Surgery Center (FSC), the facility opened as an outpatient surgery center in 1984. Within the first year, FSC was in the top 10 percent of all freestanding outpatient surgery centers in the nation, based on the number of patients served. The center`s approach to patient service was also unique. The rare combination of compassion, hospitality and surgical excellence continues to be our distinguishing factor. We were the first facility in the United States to provide elective surgery and post-surgical care in a non-hospital setting. Overwhelming popularity among patients, surgeons and staff established FSC as the leader in the nationwide trend toward elective surgery facilities. In fact, we have consistently been recognized as a top performer both in the state of California and nationally.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.